Alectinib Pharmacokinetic in Patients With NSCLC
NCT05713006
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer Stage IIIB
ALK Gene Mutation
Interventions
DRUG:
Alectinib Oral Product
Sponsor
Instituto Nacional de Cancerologia de Mexico